Compare Bristol-Myers Squibb Co (BMY) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs VanEck Australian Floating Rate ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.87 (market cap $129.94B), while VanEck Australian Floating Rate ETF trades at $50.93. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while VanEck Australian Floating Rate ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| BMY | FLOT | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $51.09 |
52-Week Low | $42.60 | $50.72 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
FLOT trades at $50.925 with minimal daily movement (+0.01%). Technical indicators show a bearish trend with all 13 moving averages signaling sell. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy as floating rate bonds like FLOT could benefit from potential rate hikes later in 2026.
FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a cash alternative with slightly higher returns than T-bills. The primary catalyst is potential Fed rate hikes, though the bearish technical picture and inflation uncertainty present near-term headwinds for price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
